Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:R-CHOP
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:consists_of |
gptkb:Rituximab
gptkb:Cyclophosphamide gptkb:Doxorubicin gptkb:Prednisone gptkb:Vincristine |
| gptkbp:developed_by |
medical researchers
|
| gptkbp:duration |
14 days
|
| gptkbp:first_introduced |
2000s
|
| gptkbp:followed_by |
maintenance therapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
R-CHOP-14
|
| gptkbp:is_a |
combination chemotherapy
|
| gptkbp:is_associated_with |
side effects
|
| gptkbp:is_compared_to |
gptkb:R-CHOP-21
|
| gptkbp:is_effective_against |
high-grade non-Hodgkin lymphoma
|
| gptkbp:is_part_of |
lymphoma treatment protocols
|
| gptkbp:is_used_for |
treatment of diffuse large B-cell lymphoma
|
| gptkbp:is_used_in |
clinical trials
|
| gptkbp:succeeded_by |
approximately 60-70%
|
| gptkbp:suitable_for |
NCCN guidelines
|